Aphria (TSE:APHA) had its price objective hoisted by CIBC from C$6.50 to C$7.00 in a research report report published on Friday morning, BayStreet.CA reports.
A number of other brokerages also recently issued reports on APHA. Jefferies Financial Group reiterated a buy rating and set a C$15.00 price target on shares of Aphria in a research report on Friday, May 24th. Cormark dropped their price target on Aphria from C$15.00 to C$14.00 in a research report on Wednesday, April 17th. Finally, Canaccord Genuity dropped their price target on Aphria from C$18.00 to C$16.00 in a research report on Wednesday, June 19th.
APHA stock opened at C$9.67 on Friday. The company has a quick ratio of 4.38, a current ratio of 5.64 and a debt-to-equity ratio of 28.19. The stock has a market cap of $1.47 billion and a price-to-earnings ratio of -138.14. Aphria has a twelve month low of C$4.76 and a twelve month high of C$22.00. The firm’s 50-day moving average is C$8.57.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Recommended Story: Buy-Side Analysts
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.